154 related articles for article (PubMed ID: 8628932)
1. [Cerebral SPECT with iodine-123 IBZM in patients with extrapyramidal system disorders: the evaluation of its sensitivity in therapy with dopaminergic drugs].
Hierholzer J; Castelli L; Cordes M; Schelosky L; Poewe W; Felix R
Radiol Med; 1996 Mar; 91(3):207-10. PubMed ID: 8628932
[TBL] [Abstract][Full Text] [Related]
2. [The differential diagnosis of Parkinson diseases--123I-IBZM-SPECT vs. the apomorphine test].
Hierholzer J; Cordes M; Schelosky L; Sander B; Böck JC; David I; Horowski R; Poewe W
Rofo; 1993 Jul; 159(1):86-90. PubMed ID: 8334264
[TBL] [Abstract][Full Text] [Related]
3. [Dopamine (D2) receptor SPECT with 123I-iodobenzamide (IBZM) in diagnosis of Parkinson syndrome].
Reiche W; Grundmann M; Huber G
Radiologe; 1995 Nov; 35(11):838-43. PubMed ID: 8657887
[TBL] [Abstract][Full Text] [Related]
4. Iodine-123-IBF SPECT evaluation of extrapyramidal diseases.
Buck A; Westera G; Sutter M; Albani C; Kung HF; vonSchulthess GK
J Nucl Med; 1995 Jul; 36(7):1196-200. PubMed ID: 7790944
[TBL] [Abstract][Full Text] [Related]
5. [The determination of cerebral dopamine (D2) receptor density by using 123I-IBZM-SPECT in Parkinson disease patients].
Hierholzer J; Cordes M; Schelosky L; Barzen G; Poewe W; Henkes H; Keske U; Horowski R; Felix R
Rofo; 1992 Oct; 157(4):390-8. PubMed ID: 1391843
[TBL] [Abstract][Full Text] [Related]
6. [Initial experiences with 123-Iodine-IBZM neuroreceptor scintigraphy in extrapyramidal disorders].
Pávics L; Dibó G; Ambrus E; Séra T; Vécsei L; Csernay L
Orv Hetil; 2000 May; 141(20):1073-7. PubMed ID: 10851890
[TBL] [Abstract][Full Text] [Related]
7. Correlation of clinical response in apomorphine test with D2-receptor status as demonstrated by 123I IBZM-SPECT.
Schelosky L; Hierholzer J; Wissel J; Cordes M; Poewe W
Mov Disord; 1993 Oct; 8(4):453-8. PubMed ID: 8232354
[TBL] [Abstract][Full Text] [Related]
8. [123]IBZM binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimetic therapy.
Schwarz J; Tatsch K; Gasser T; Arnold G; Oertel WH
Mov Disord; 1997 Nov; 12(6):898-902. PubMed ID: 9399212
[TBL] [Abstract][Full Text] [Related]
9. Loss of dopamine-D2 receptor binding sites in Parkinsonian plus syndromes.
Hierholzer J; Cordes M; Venz S; Schelosky L; Harisch C; Richter W; Keske U; Hosten N; Mäurer J; Poewe W; Felix R
J Nucl Med; 1998 Jun; 39(6):954-60. PubMed ID: 9627325
[TBL] [Abstract][Full Text] [Related]
10. Iodine-123-iodobenzamide binding in parkinsonism: reduction by dopamine agonists but not L-Dopa.
Schwarz J; Oertel WH; Tatsch K
J Nucl Med; 1996 Jul; 37(7):1112-5. PubMed ID: 8965179
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of D2 receptor scintigraphy (123I-IBZM) with cerebral perfusion (99m-Tc-HMPAO) in extrapyramidal disorders].
Saur HB; Bartenstein P; Schober O; Oberwittler C; Lerch H; Masur H
Nuklearmedizin; 1994 Oct; 33(5):184-8. PubMed ID: 7997375
[TBL] [Abstract][Full Text] [Related]
12. 123I-iodobenzamide-SPECT in 83 patients with de novo parkinsonism.
Schwarz J; Tatsch K; Arnold G; Ott M; Trenkwalder C; Kirsch CM; Oertel WH
Neurology; 1993 Dec; 43(12 Suppl 6):S17-20. PubMed ID: 8264906
[TBL] [Abstract][Full Text] [Related]
13. Lateralized differences in iodine-123-IBZM uptake in the basal ganglia in asymmetric Parkinson's disease.
Knable MB; Jones DW; Coppola R; Hyde TM; Lee KS; Gorey J; Weinberger DR
J Nucl Med; 1995 Jul; 36(7):1216-25. PubMed ID: 7790947
[TBL] [Abstract][Full Text] [Related]
14. 123I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism.
Schwarz J; Tatsch K; Gasser T; Arnold G; Pogarell O; Künig G; Oertel WH
Mov Disord; 1998 Jan; 13(1):16-9. PubMed ID: 9452320
[TBL] [Abstract][Full Text] [Related]
15. IBZM-SPECT as predictor for dopamimetic responsiveness of patients with de novo parkinsonian syndrome.
Oertel WH; Schwarz J; Tatsch K; Arnold G; Gasser T; Kirsch CM
Adv Neurol; 1993; 60():519-24. PubMed ID: 8420182
[TBL] [Abstract][Full Text] [Related]
16. Continuous intravenous infusion of iodine-123-IBZM for SPECT determination of human brain dopamine receptor occupancy by antipsychotic agent RWJ-37796.
Seibyl JP; Zea-Ponce Y; Brenner L; Baldwin RM; Krystal JH; Offord SJ; Mochoviak S; Charney DS; Hoffer PB; Innis RB
J Nucl Med; 1996 Jan; 37(1):11-5. PubMed ID: 8543979
[TBL] [Abstract][Full Text] [Related]
17. SPECT imaging of dopamine D2 receptors with 123I-IBZM: initial experience in controls and patients with Parkinson's syndrome and Wilson's disease.
Tatsch K; Schwarz J; Oertel WH; Kirsch CM
Nucl Med Commun; 1991 Aug; 12(8):699-707. PubMed ID: 1838142
[TBL] [Abstract][Full Text] [Related]
18. Comparison of iodine-123-epidepride and iodine-123-IBZM for dopamine D2 receptor imaging.
Leslie WD; Abrams DN; Greenberg CR; Hobson D
J Nucl Med; 1996 Oct; 37(10):1589-91. PubMed ID: 8862288
[TBL] [Abstract][Full Text] [Related]
19. Comparison of diffusion-weighted imaging and [123I]IBZM-SPECT for the differentiation of patients with the Parkinson variant of multiple system atrophy from those with Parkinson's disease.
Seppi K; Schocke MF; Donnemiller E; Esterhammer R; Kremser C; Scherfler C; Diem A; Jaschke W; Wenning GK; Poewe W
Mov Disord; 2004 Dec; 19(12):1438-45. PubMed ID: 15390073
[TBL] [Abstract][Full Text] [Related]
20. Iodine-123-epidepride-SPECT: studies in Parkinson's disease, multiple system atrophy and Huntington's disease.
Pirker W; Asenbaum S; Wenger S; Kornhuber J; Angelberger P; Deecke L; Podreka I; Brücke T
J Nucl Med; 1997 Nov; 38(11):1711-7. PubMed ID: 9374338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]